MedImmune LLC clinical trials

Acquired by AstraZeneca, Jun 1, 2007 · source ↗

The registry lists 271 studies whose lead sponsor is MedImmune LLC. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 271. List all 271 → · All AstraZeneca studies →

• Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination StudyActive, not recruitingNCT03381274Phase 1/2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study to Evaluate MEDI5752 in Subjects With Advanced Solid TumorsActive, not recruitingNCT03530397Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCActive, not recruitingNCT04068610Phase 1/2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular CarcinomaActive, not recruitingNCT02519348Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant MesotheliomaActive, not recruitingNCT01843374Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study of Durvalumab (MEDI4736) and Monalizumab in Solid TumorsActive, not recruitingNCT02671435Phase 1/2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell CarcinomaActive, not recruitingNCT04522323Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of AgeTerminatedNCT01997450

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.CompletedNCT03555994Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCCompletedNCT03822351Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid TumorsCompletedNCT03946800Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.CompletedNCT03611556Phase 1/2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.CompletedNCT02503774Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid TumorsCompletedNCT03889275Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedNCT03596177Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.CompletedNCT04019561Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• Safety and Efficacy of MEDI0457 and Durvalumab in Participants With Human Papilloma Virus (HPV) Associated Recurrent/Metastatic Head and Neck CancerCompletedNCT03162224Phase 1/2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.CompletedNCT04261075Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).CompletedNCT02088112Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• MEDI2228 in Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT03489525Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerCompletedNCT03794544Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial InfarctionCompletedNCT03578809Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United StatesCompletedNCT00121108Phase 3

  Sponsor listed in the registry: MedImmune LLC · First submitted before MedImmune LLC became part of AstraZeneca

• N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum DisordersCompletedNCT02200770Phase 2/3

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV InfectionCompletedNCT00192504Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted before MedImmune LLC became part of AstraZeneca

• A Phase 2 Study to Evaluate Immune Responses of FluMist®CompletedNCT00461981Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted before MedImmune LLC became part of AstraZeneca

• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)CompletedNCT00192231Phase 3

  Sponsor listed in the registry: MedImmune LLC · First submitted before MedImmune LLC became part of AstraZeneca

• A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy InfantsCompletedNCT00192348Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted before MedImmune LLC became part of AstraZeneca

• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy AdultsCompletedNCT00192192Phase 3

  Sponsor listed in the registry: MedImmune LLC · First submitted before MedImmune LLC became part of AstraZeneca

• Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of AgeCompletedNCT00128167Phase 3

  Sponsor listed in the registry: MedImmune LLC · First submitted before MedImmune LLC became part of AstraZeneca

• Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and OlderCompletedNCT00192153Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted before MedImmune LLC became part of AstraZeneca

• Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)CompletedNCT00192387Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted before MedImmune LLC became part of AstraZeneca

• A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) IllnessCompletedNCT00421304Not applicable

  Sponsor listed in the registry: MedImmune LLC · First submitted before MedImmune LLC became part of AstraZeneca

• A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese ParticipantsCompletedNCT03625778Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) IllnessTerminatedNCT00435227Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted before MedImmune LLC became part of AstraZeneca

• A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced MalignanciesCompletedNCT02118337Phase 1/2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Phase 1/2 Study to Evaluate MEDI4736CompletedNCT01693562Phase 1/2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated SubjectsCompletedNCT02696902Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid TumorsCompletedNCT02900157Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung CancerTerminatedNCT01268059Phase 1/2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).CompletedNCT00768079Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese ParticipantsCompletedNCT03096795Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRCWithdrawnNCT04145193Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple DosesTerminatedNCT03362593Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes MellitusCompletedNCT03654313Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.CompletedNCT03089645Phase 1

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ AdenocarcinomaCompletedNCT02340975Phase 1/2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedNCT03745937Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast CancerCompletedNCT01446159Phase 2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca

• A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell MalignanciesCompletedNCT00983619Phase 1/2

  Sponsor listed in the registry: MedImmune LLC · First submitted after MedImmune LLC became part of AstraZeneca